Key Documents

View All Documentation

P4050000

Pyrazinamide

Name: Pyrazinamide
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Pyrazinecarboxamide, Pyrazinamide, Pyrazinoic acid amide

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₅H₅N₃O

CAS Number:

98-96-4

Molecular Weight:

123.11

UNSPSC Code:

41116107

NACRES:

NA.24

PubChem Substance ID:

329820195

MDL number:

MFCD00006132

Beilstein/REAXYS Number:

112306

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

grade

pharmaceutical primary standard

API family

pyrazinamide

manufacturer/tradename

EDQM

mp

189-191 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

NC(=O)c1cnccn1

InChI

1S/C5H5N3O/c6-5(9)4-3-7-1-2-8-4/h1-3H,(H2,6,9)

InChI key

IPEHBUMCGVEMRF-UHFFFAOYSA-N

Description

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Pyrazinamide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Still not finding the right product?

Explore all of our products under Pyrazinamide

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis.

A Somoskovi et al.

Respiratory research, 2(3), 164-168 (2001-11-01)

Multidrug-resistant (MDR) strains of Mycobacterium tuberculosis have emerged worldwide. In many countries and regions, these resistant strains constitute a serious threat to the efficacy of tuberculosis control programs. An important element in gaining control of this epidemic is developing an

Adjusted indirect treatment comparison of the bioavailability of WHO-prequalified first-line generic antituberculosis medicines.

L Gwaza et al.

Clinical pharmacology and therapeutics, 96(5), 580-588 (2014-07-06)

Approval of generic medicines is based on bioequivalence with the innovator product, but it is not unusual for generics to be interchanged with each other. This study investigated the differences in bioavailability between World Health Organization-prequalified antituberculosis generics by means

The near future: improving the activity of rifamycins and pyrazinamide.

D A Mitchison et al.

Tuberculosis (Edinburgh, Scotland), 90(3), 177-181 (2010-04-13)

While we wait for improved new anti-tuberculosis drugs, the main aim for improving current treatment should be to optimize the use of the two current drugs, rifampicin and the pro-drug pyrazinamide, which are responsible to a similar extent for the

View All Related Papers

Global Trade Item Number

SKU	GTIN
P4050000	04061834373520